Early treatment with Copaxone
(glatiramer acetate) in patients
with Clinically Isolated Syndrome
and lesions suggestive of multiple
sclerosis may delay the diagnosis of
clinically definite multiple sclerosis
(CDMS) by more than two-anda-
half years compared to later
treatment, new research reveals.
Associate Professor John King,
Chairman of Royal Melbourne
Hospital Neuroscience Foundation
said that the results reinforce the
existing weight of data supporting
the efficacy of Copaxone in
reducing relapses.The above article was sent to subscribers in Pharmacy Daily's issue from 08 Aug 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Aug 13
NEW data from the Australian Institute of Health and Welfare has revealed around 43% (or 8.5 million) of Australians aged 16-85 have experienced a mental disorder at some point in their lives.
THE Pharmacy Guild of Australia has formally expressed its concerns regarding the potential merger between Sigma and Chemist Warehouse (PD 07 Dec 2023) to the Australian Competition and Consumer Commission (ACCC).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.